Open AccessLong term result of intravitreal bevacizumab in a patient newly transformed to proliferative macular telangiectasia type 2
Author(s) -
Abdullah Özkaya,
Zeynep Alkın,
Yalçın Karaküçük,
Ahmet Yazıcı,
Ahmet Demirok
Publication year - 2013
Publication title -
middle east african journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.357
H-Index - 25
eISSN - 0975-1599
pISSN - 0974-9233
DOI - 10.4103/0974-9233.120005
Subject(s) - macular telangiectasia , medicine , bevacizumab , term (time) , ophthalmology , telangiectasia , optometry , dermatology , surgery , fluorescein angiography , retinal , chemotherapy , physics , quantum mechanics
The clinical and imaging findings and therapeutic outcomes of intravitreal bevacizumab injection in a patient with macular telangiectasia type 2 are described. The patient first presented with the non-proliferative stage of the disease for 4 months, then the disease transformed to the proliferative stage. In the proliferative period, the patient was treated with intravitreal bevacizumab injections as-clinically warranted. Over a follow up period lasting 26 months, the patient received 6 intravitreal bevacizumab injections, the visual acuity improved from 20/100 to 20/40, the central retinal thickness decreased from 318 microns to 198 microns. This case implies that the patients with non-proliferative macular telangiectasia type 2 should be followed carefully for proliferative transformation, and intravitreal bevacizumab treatment seems to be effective for proliferative macular telangiectasia type 2.